Recent studies have shown that inhibiting PD-1 or programmed cell death-ligand 1 (PD-L1) restores T cell function, enabling the immune system to recognize and destroy cancer cells, suggesting their potential as promising therapeutic targets for NSCLC treatment [15-17]. This evidence concerns the gene CD274 and cancer.